摘要
目的:对关于卡培他滨联合放疗治疗食管癌的相关文献及研究进行Meta分析,明确卡培他滨在食管癌同步放化疗中的作用。方法检索CBM、CNKI、万方数据库、VIP数据库、PubMed、Embase等电子数据库,检索截止时间为2015年7月19日,纳入关于卡培他滨联合放疗治疗食管癌患者的病例对照研究20篇,采用病例-对照研究的NOS质量评价标准对纳入研究进行质量评价,应用Stata 13.1软件进行数据分析。结果与单纯放疗组相比,卡培他滨联合放疗可以提高食管癌患者的近期有效率(P=0.000)和2年生存率(P=0.002),但却增加了胃肠道反应(P=0.004)和手足综合征的发生率(P=0.000)。结论卡培他滨联合放疗可以作为不能手术或不愿意手术食管癌患者综合治疗的一种选择,能够提高患者治疗的近期有效率和2年生存率。
Objective To evaluate the advantage and clinical value of capecitabine con-current radiotherapy for esophageal carcinoma. Methods We searched the electronic databases of CBM,CNKI, Wangfang,VIP,PubMed and Embase for case-control study that about single capecitabine concurrent ra-diotherapy for esophageal carcinoma,the date before July 19,2015. Quality of the included study was assessed by Newcastle-Ottawa quality assessment scale for case-control study,and all calculations of the extracted data were performed using Stata 13. 1 . Results Twenty studies were included in Meta-analy-sis. The results of Meta-analysis showed that capecitabine concurrent radiotherapy for esophageal carcino-ma compared with control group,could increased the recent curative effect(P =0. 000)and 2 years overall survival( P=0. 002 ),but also increased the incidence of gastrointestinal adverse reactions( P=0. 004 )and hand foot syndrome( P=0. 000 ). Conclusions It is a choose for unresectable esophageal carcinoma patients to treatment by capecitabine concurrent radiotherapy,because it can increase the re-cent curative effect and 2 years overall survival.
出处
《中国实用医刊》
2016年第16期12-16,共5页
Chinese Journal of Practical Medicine
关键词
食管癌
卡培他滨
放疗
META分析
Esophageal carcinoma
Capecitabine
Radiotherapy
Meta-analysis